how to PLAY it

year-to-date, nasdaq’s biotechnology index is up over 25%, testament to a strong pipeline of promising remedies and a real health care revolution for patients and investors. last september, our top analyst recommended three oncology companies that gilead sciences might acquire: incyte, then at $94; Kite at $55; and puma at $68. in august, gilead said it would buy Kite for $180 a share, or $11.9 billion. Incyte and puma now trade at $123 and $103, respectively.

another stock investors should consider is colorado’s Clovis Oncology, our current top pick in cancer treatments. clovis is working on parp inhibitor, a promising new technology for treating prostate and ovarian cancers. We think clovis’ $3.4 billion market cap and impressive technology portfolio make it a great acquisition candidate.